Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
China's lowSolomon Islanders vote in key election for their country, region — Radio Free AsiaMotoGP racing for new momentum in America, with hopes of riding an F1Amed Rosario's RBI infield single in the 13th inning lifts the Rays to a 7Watch What Happens Live: Kristen Doute says The Valley coCalifornia game store thief is wrestled to ground during robberyDozens of Russian athletes are likely to qualify for the Paris Olympics. Will Moscow let them go?Jamelia reveals the REAL reason for her sudden exit from HollyoaksTom Hollander reveals how he considered letting himself go to become a 'fat actor' to get workReynaldo López pitches 6 scoreless innings, Braves beat Astros 6
2.2538s , 6501.4765625 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Worldly Workshop news portal